Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor‐2‐positive breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|142|4|844-853

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.142, Iss.4, 2018-02, pp. : 844-853

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 3032-3040

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

By  

Oncology Research and Treatment, Vol. 35, Iss. 12, 2012-10 ,pp. : 740-745

Karger

Access to resources Recommend Favorite

Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact

By  

Oncology, Vol. 84, Iss. 3, 2012-12 ,pp. : 150-157

Karger

Access to resources Recommend Favorite

Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 111-116

Bentham Science Publishers

Access to resources Recommend Favorite

Neoadjuvant Therapy for HER2-positive Breast Cancer

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 2, 2017-05 ,pp. : 81-92

Bentham Science Publishers

Access to resources Recommend Favorite